Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Welgene Biotech Co., Ltd. (6661:TWSE), powered by AI.
Welgene Biotech Co., Ltd. is currently trading at $16.20. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Welgene Biotech Co., Ltd. on Alpha Lenz.
View Welgene Biotech Co., Ltd.'s valuation metrics on Alpha Lenz.
“Welgene Biotech Co., Ltd.'s ROE is 0.5%. Explore profitability and growth together.”
Ask for details →Welgene Biotech Co., Ltd. is a biotechnology company based in Taipei, Taiwan, specializing in advanced genetic testing services and molecular diagnostic solutions. Established in 2003, the company operates two principal business segments: biotechnology testing and medical equipment sales. In its core testing segment, Welgene Biotech leverages technologies such as DNA microarray, next-generation sequencing, and real-time quantitative polymerase chain reaction (PCR) to provide precise laboratory testing for universities, hospitals, and pharmaceutical companies. Its medical equipment segment supplies essential diagnostic and research tools to various institutions in the health technology sector. Welgene Biotech plays a significant role in the Taiwanese healthcare and life sciences market by enabling personalized medicine and supporting clinical research initiatives. With a focus on innovation and quality, the company contributes to the broader advancement of medical science and the improvement of healthcare outcomes.
“Welgene Biotech Co., Ltd.'s ROE is 0.5%. Explore profitability and growth together.”
Ask for details →Welgene Biotech Co., Ltd. (ticker: 6661) is a company listed on TWSE in the Healthcare sector (Diagnostics & Research).
The current price is 16.2 with a P/E ratio of -x and P/B of -x.
ROE is 0.47% and operating margin is 0.02%. Annual revenue is $376M.